Regulatory2026-06-01

Camzyos (mavacamten) - (SCOUT-HCM)

Bristol-Myers Squibb CompanyBMY
Indication
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Stage
phase5
Event
Regulatory Decision